Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Strategies to reduce the high cost of hepatitis C antiviral treatment: a literature review

Teachout, Jocelin (2017) Strategies to reduce the high cost of hepatitis C antiviral treatment: a literature review. Master Essay, University of Pittsburgh.

[img] Microsoft Word
Submitted Version

Download (141kB)

Abstract

Hepatitis C infection is a chronic, debilitating disease with complications such as liver cancer and liver cirrhosis. In the United States, hepatitis C infection can be cured only with direct acting antiviral treatment. However, the cost of hepatitis C antiviral treatment is expensive, hindering many Americans from receiving treatment. Insurance companies and pharmaceutical companies control access to hepatitis C antiviral treatment as out-of-pocket costs are unaffordable for most individuals. A literature review was conducted to investigate strategies to reduce the high cost of hepatitis C antiviral treatment using PubMed database. The research question of “What are current or future strategies that could reduce the high cost of hepatitis C antiviral treatment in the US market to increase access?” focused this literature review’s purpose. Relevant studies were those published from 2013 to present that included strategies to decrease the cost of hepatitis C antiviral treatment. Articles were excluded if they included a genotype other than genotype 1, represented studies conducted in a country other than the United States, or a specific clustering of individuals in the title such as injection drug users, at-risk populations, and prison inmates. Thirty-one studies met the criteria for inclusion in this literature review. Fifteen articles indicated increased market competition (48.3% of the total included articles) as a strategy to decrease the cost of hepatitis C antiviral treatment. Modifications to the pharmaceutical industry were emphasized in 12 articles (38.7% of the total included articles) such as promoting competition, research of equivalent drugs, and partnerships with other pharmaceutical companies as a means of decreasing hepatitis C antiviral treatment costs. Eleven articles suggested that stakeholder involvement (35.5% of the total included articles) could help to reduce hepatitis C antiviral treatment costs. Eight studies suggested that business/finance industry modifications (25.8% of the total included articles) could lower hepatitis C antiviral treatment costs. These studies assist in developing strategies to reduce the high financial burden on people living with hepatitis C and furthering public health significance in reducing hepatitis C transmission.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Other Thesis, Dissertation, or Long Paper (Master Essay)
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Teachout, Jocelinjrt83@pitt.edujrt83
Contributors:
ContributionContributors NameEmailPitt UsernameORCID
Committee ChairFriedman, Mackeymrf9j@pitt.edumrf9UNSPECIFIED
Committee MemberHawk, Marymeh96@pitt.edumeh96UNSPECIFIED
Date: 2017
Date Type: Submission
Number of Pages: 53
Institution: University of Pittsburgh
Schools and Programs: Graduate School of Public Health > Infectious Diseases and Microbiology
Degree: MPH - Master of Public Health
Thesis Type: Master Essay
Refereed: Yes
Date Deposited: 17 Jul 2018 17:00
Last Modified: 17 Jul 2018 17:00
URI: http://d-scholarship.pitt.edu/id/eprint/33417

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item